



Geron to Present at the 21st Annual Needham Virtual Healthcare Conference

4/6/2022

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, plans to present a company overview at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET.

A live webcast of the presentation will be available through the Investor Relations section of Geron's website under **Events**. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMPactMF in refractory myelofibrosis.

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20220406005098/en/>

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation